The Bull Market and Beyond: 3 Stocks Just Waiting to Soar

Earlier this year. Standard & Poor's 500The record highs in the indexes prove that we are indeed in a bull market, which is good news for growth stocks. This is good news for growth stocks. The market environment favors companies that are expanding rapidly and investing in their businesses. Some of these companies have benefited greatly, leading the way, while others have been left behind, despite the fact that they offer exciting long-term prospects.

These are the companies to catch today, because they're poised for growth. There are three stocks of particular interest right now, all of which are leaders in the biotech sector - a sector full of innovations that could lead to revenue growth and stock price performance. Let's take a look at these stocks that could climb in a bull market and beyond.

1. Moderna

Moderna (NASDAQ Resonance: MRNA)Shares soared in the early days of the pandemic as the company's coronavirus vaccine generated billions of dollars in revenue. But as demand for the vaccine declined, so did the biotech's shares. Investors are concerned about future growth, as the vaccine is currently the company's only commercialized product.

But there are reasons to be optimistic about Moderna's long-term prospects, and the company may even launch a second product as soon as this year. The regulatory agency is reviewing Moderna's RSV vaccine candidate and may announce a decision in the next few months. The company is also developing several other late-stage candidates, and said last year that it aims to launch up to 15 products over the next five years.

Even if Moderna achieves only a small portion of its goals, it will drive growth in the coming years. The company estimates the total addressable market size for its infectious disease vaccine portfolio to be about $52 billion. As a result, Moderna looks very cheap right now, trading at about 8.5 times forward earnings estimates.

2. Intellia Therapeutics

Intellia Therapeuticsfirms(NASDAQ: NTLA)Specializes in CRISPR gene editing, which repairs faulty genes that cause disease. The technique involves cutting DNA at specific locations to enable a natural repair process.

The innovative company does not have a product on the market yet, but it could be commercialized soon and is on the verge of several key catalysts and targets.

Intellia recently injected the first patient in its NTLA-2001 Phase 3 trial for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR). Intellia's goal is to complete patient enrollment in this study and the pivotal study of NTLA-2002 for the treatment of hereditary agranulocytosis (HAE) in the next three years, and then apply for regulatory approval for NTLA-2002 in 2026. ATTR is caused by a buildup of misfolded proteins that affect multiple organs, while HAE is a disease that causes excessive and unpredictable swelling.

It's a great time for Intellia to be close to the Koon terminals. Fellow travelersCRISPR TherapeuticsThe company recently received approval for the world's first CRISPR-based therapeutic regimen, signaling that the regulatory agencies are open to this new technology. As such, now is a good time to get into Intellia stock.

3. Ginkgo Bio Inc.

Ginkgo Bioworks (NYSE: DNA)is a cellular engineering and biosafety company with the potential to change the rules of the game in a variety of industries. A particularly interesting opportunity is in healthcare, where the company is growing its business, with biopharmaceutical revenues soaring 40% last year over the previous year.

For example, the company's platform can help drugmakers select the best molecules to improve their manufacturing processes, and Ginkgo has partnered withglorious ,come with a giftA number of well-known companies, including Carbide, have initiated cooperation. Ginkgo is also increasing the number of new biologics projects from 7 in 2020 to 23 today.

Ginkgo is currently in a growth mode, adding more and more cellular engineering to its portfolio of carbs and strengthening its biosafety business with a focus on long-term infrastructure, which will lead to a recurring revenue model for the biosafety division.

Ginkgo has the financial wherewithal to keep growing, with nearly $950 million in cash, and has indicated that it has years to achieve its earnings and other goals. All of this could lead to explosive growth for Ginkgo stock, meaning an investment today could pay off in the long run.

Should you invest $1,000 in Moderna now?

Before buying Moderna stock, consider the following:

Motley Fool Stock AdvisorA team of analysts has just named what they think is the best name for investors to buy right now.10Only ...... and Moderna is not one of them. The 10 stocks that made the list could generate huge returns in the coming years.

Consider April 15, 2005Nvidia) on the list at ...... If you invest $1,000 at the time of our recommendation, theYou will own 539,230dollar! *Stock Advisor provides easy-to-use stock investment tools for investors.

Stock AdvisorProvides investors with an easy-to-understand blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock recommendations per month. Stock Advisor The service has contributed to the S&P 500 Index's return since 2002.translate twiceMuch*.

View 10 Gift Certificates

*Stock Advisory Rates as of April 8, 2024

Adria Cimino does not own any of the stocks mentioned above. the Motley Fool holds recommended stocks CRISPR Therapeutics, Intellia Therapeutics and Terry Ray. the Motley Fool recommends Moderna. the Motley Fool has a disclosure policy.

Bull Market and Beyond: 3 Stocks Waiting to Rise was originally published by The Motley Fool.